Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 3/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21934559 | 0.87 | NPC1 (0.35) | ALDH1A1L3MBTL1NPC1CRBNMAP3K14 | |
| SCHEMBL22146994 | 0.87 | NPC1 (0.41) | ALDH1A1L3MBTL1NPC1LMNAKDM4E | |
| SCHEMBL18515841 | 0.84 | MAP3K14 (0.39) | ALDH1A1L3MBTL1NPC1LMNACRBN | |
| SCHEMBL18799306 | 0.79 | CCR2 (0.36) | CCR2CCR1CCR5CXCR4LMNA | |
| SCHEMBL21533866 | 0.74 | NPC1 (0.36) | ALDH1A1L3MBTL1NPC1CCR2CRBN | |
| SCHEMBL11039141 | 0.74 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1NPC1LMNAKDM4E | |
| SCHEMBL16682230 | 0.73 | CRBN (0.41) | ALDH1A1L3MBTL1NPC1LMNACRBN | |
| SCHEMBL21884191 | 0.73 | CCR2 (0.34) | ALDH1A1L3MBTL1CCR2CCR1CCR5 | |
| SCHEMBL22374247 | 0.72 | CRBN (0.38) | CRBNKMT2A | |
| SCHEMBL6123578 | 0.68 | MAP3K14 (0.44) | L3MBTL1NPC1LMNACRBNMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | LNPEP, DNPEP, QPCT | ALDH1A1 2349/4885L3MBTL1 415/4885NPC1 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.